Combination approach shows promise for treating rare, aggressive cancers A research team has shown that that combining pembrolizumab, an immunotherapy drug, with standard chemotherapy can improve treatment outcomes for patients with small cell bladder cancer and small cell/neuroendocrine prostate cancer.
https://www.sciencedaily.com/r....eleases/2024/11/2411